Savran Technologies

Executive Summary

Savran Technologies is a US-based diagnostics company pioneering a non-invasive urine test for the early prediction of preeclampsia, a leading cause of maternal and fetal morbidity. The test leverages the company's proprietary platform for capturing and detecting ultra-rare cells, enabling prediction months before clinical symptoms appear. By addressing the critical gap in prenatal care, Savran aims to reduce emergency interventions and improve outcomes for millions of pregnancies worldwide. The company, headquartered in Cambridge, MA, was founded in 2016 and operates in the women's health diagnostics space with a first-of-its-kind approach. The market opportunity is significant, as preeclampsia affects 5-8% of pregnancies globally, and current screening methods lack predictive accuracy. Savran's urine-based test offers a convenient, scalable solution with potential for integration into routine prenatal care. If successful, the company could transform maternal health risk assessment, capturing a substantial share of the prenatal diagnostics market. Key milestones include clinical validation, regulatory clearance, and commercialization partnerships. Savran's technology platform also holds promise for broader applications in rare cell detection, extending its addressable market beyond obstetrics.

Upcoming Catalysts (preview)

• Q4 2026Pivotal Clinical Trial Results60% success
• Q2 2026FDA Breakthrough Device Designation70% success
• Q3 2026Strategic Partnership with a Diagnostics Leader50% success